Bluebird Pushes For Zynteglo Pricing Of Five €315K Annual Installments

Jun 14 2019

• By Jessica Merrill

Listen to this article

CEO Nick Leschly talked to Scrip about the European payment strategy for the one-time gene therapy, which will cost €1.575m over five years if treatment is successful.

Saving account and money finance banking for prepare concept, Row of coin stack growing business, Save money retirement concept, Savings money for future - Image

bluebird bio Inc. is resolute in its determination to negotiate a five-year €315,000 ($356,000) annual payment model for its new gene therapy Zynteglo in Europe. The company laid out the price of the one-time gene therapy on 14 June in a strategy meant to manage some of the sticker shock associated with a seven-figure drug price by balancing the cost with a risk-based model annuitized over five years.

The price of Zynteglo is set at €1.575m ($1.78m) over the five years, if the treatment is successful, based on...

More from Drug Pricing

How A New Healthcare Dialogue Is Driving Market Access In Mexico
Nov 06 2025
Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.
India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2
Oct 14 2025
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
Sponsored By
Nancy Tests SPARC-931 Part 8
This is a short description. This is a short description.
As More DLL3 Bispecifics Advance, Doctors Are Adjusting To CRS, ICANS
Mar 10 2025
• By Mandy Jackson
Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance
Jul 15 2026
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone
Jun 18 2026
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Finance Watch: Biopharma IPOs On The Upswing, Including Ex-US Offerings
Jun 17 2026
ghghghghghjhjhjhj